WO2015163284A1 - 液体口腔用組成物及びその凍結復元性向上方法 - Google Patents
液体口腔用組成物及びその凍結復元性向上方法 Download PDFInfo
- Publication number
- WO2015163284A1 WO2015163284A1 PCT/JP2015/061990 JP2015061990W WO2015163284A1 WO 2015163284 A1 WO2015163284 A1 WO 2015163284A1 JP 2015061990 W JP2015061990 W JP 2015061990W WO 2015163284 A1 WO2015163284 A1 WO 2015163284A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- emulsion
- oil
- composition
- content
- liquid oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
Definitions
- the present invention relates to an emulsion-blended liquid oral composition and a method for improving the freeze-restorability thereof, which are excellent in appearance stability (freeze-restorability) at the time of freeze-thawing and can give a good feeling of use.
- Patent Document 1 JP-A-2005-179231
- Patent Document 2 Japanese Patent Laid-Open No. 2005-179231
- Patent Document 3 Japanese Patent Laid-Open No. 11-335253
- Patent Document 4 Japanese Patent No. 5043588,
- Patent Document 5 Special No. 2011-168506,
- Patent Document 6 Japanese Patent Application Laid-Open No. 2012-12394
- Patent Document 7 International Publication No. 2011/115034
- Patent Document 8 International Publication No. 2011/0777847
- the emulsion composition is a state in which the water phase and the oil phase are mixed via an emulsifier, and the emulsion is agglomerated or coalesced due to long-term storage, mechanical vibration, rapid temperature change, etc.
- the appearance changes due to emulsion breakage, causing problems in quality, and in the above patent document, improvement of storage stability has been proposed. There was still room for improvement in the restoration of appearance.
- the said patent document does not mention the recoverability at the time of freezing by low temperature severe condition preservation
- the present invention has been made in view of the above circumstances, and is excellent in appearance stability (freezing / restoring property) at the time of freezing and thawing, and can also give a good feeling of use, and a liquid oral composition containing an emulsion and its It is an object of the present invention to provide a method for improving freezing and restoring properties.
- an N-acyl taurine salt When B) is blended, the appearance stability (freezing / restoring property) at the time of freezing and thawing is improved, a stable formulation appearance can be given, and a good feeling of use can be given, and the present invention has been made. It was.
- the appearance stability at the time of freezing and thawing of the emulsion-containing liquid preparation specifically frozen at a low temperature of ⁇ 20 ° C.
- the restorability of the appearance afterwards was remarkably improved. Even after freezing and thawing work of freezing at ⁇ 20 ° C. for 24 hours and then allowed to stand at 25 ° C. for 24 hours to thaw, the liquid could be recovered. Freezing and restoring properties that can suppress changes in white turbidity are provided.
- the combination of the components (A) and (B) specifically suppresses aggregation and coalescence of the emulsion due to a rapid temperature change (enlargement of the emulsion particle size), and improves the stability of the emulsion.
- it effectively imparts a refreshing feeling to the oral cavity and provides a good feeling of use. give.
- the content of the oily component contained in the emulsion particles of the emulsion (A) is within a specific range with respect to the entire composition, and is also contained in the emulsion particles of the emulsion (A).
- the content of the oily component / (the content of the N-acyl taurine salt (B)) is within the specific ratio range, the appearance stability (freezing / restoring property) upon freezing and thawing and the feeling of use are further improved. Therefore, it is preferable to mix
- isopropylmethylphenol (C) when isopropylmethylphenol (C) is blended, the above-described effects are excellent and the oral biofilm bactericidal power of isopropylmethylphenol is sufficiently expressed, and a high periodontal pathogenic biofilm bactericidal effect can be provided. Furthermore, when the fragrance (D) containing clove oil and / or thyme oil is blended, the pungent taste derived from the N-acyl taurine salt (B) can be suppressed, the irritation caused by the pungent taste can be suppressed, and a better feeling of use can be obtained. Can be granted.
- the present invention provides the following liquid oral composition and a method for improving the freeze-restoration thereof.
- the oily component contains an emulsion (A) composed of a liquid fat at 25 ° C. and an N-acyl taurine salt (B), and the content of the N-acyl taurine salt (B) is 0.2 to 0.8 mass. % Liquid oral composition characterized by the above-mentioned.
- the oily component is one or more oils and fats selected from olive oil, camellia oil, castor oil, and trifatty acid glyceryl having 6 to 12 carbon atoms.
- emulsion (A) is an O / W type emulsion in which a polyhydric alcohol and water are used as a dispersion medium and an oil component is emulsified with a nonionic surfactant.
- Oral composition [6] The liquid oral composition according to any one of [1] to [5], further comprising 0.01 to 0.2% by mass of isopropylmethylphenol (C).
- the liquid oral cavity composition comprising 0.2 to 0.8% by mass of N-acyl taurine salt (B) in a liquid oral cavity composition in which an oily component is an emulsion (A) composed of liquid oil at 25 ° C.
- a method for improving the freezing and restoring properties of a composition [11] [10] The method for improving freezing and restoring properties of a liquid oral composition according to [10], wherein the content of the oil component contained in the emulsion particles of the emulsion (A) is 0.02 to 1.0% by mass of the whole composition.
- [14] The method for improving freezing and restoring properties of a liquid oral composition according to any one of [10] to [13], wherein the total content of the surfactant is 0.1 to 2% by mass.
- [15] The method for improving freezing and restoring properties of a liquid oral composition according to any one of [10] to [14], wherein the ethanol content in the composition is 100 ppm or less.
- [16] The method for improving the freezing and restoring properties of a liquid oral composition according to any one of [10] to [15], further comprising 0.01 to 0.2% by mass of isopropylmethylphenol (C).
- the perfume (D) containing clove oil and / or thyme oil is blended so that the content of the clove oil and / or thyme oil is 0.00001 to 0.01% by mass of the whole composition.
- isopropylmethylphenol can be blended to impart high oral biofilm sterilizing power.
- composition for liquid oral cavity of the present invention contains an emulsion (A) comprising an oily fat as an oily component at 25 ° C. and an N-acyl taurine salt (B).
- Emulsion (A) is an oil component in which the oil component contained in the emulsion particles consists of liquid oil at 25 ° C.
- an O / W type (oil-in-water type) emulsion obtained by emulsifying the above fats and oils with a polyhydric alcohol, water or the like as a dispersion medium can be used. It is preferable to add and mix an O / W type emulsion.
- the oil droplet particles of the O / W type emulsion are dispersed in the liquid oral composition, and the dispersion medium is mixed with the aqueous phase of the liquid oral composition and exists as an O / W type emulsion.
- oils and fats that are liquid at 25 ° C. which are oily components, include liquid oils and fats such as olive oil, camellia oil and castor oil, and tri-fatty acid glyceryl having a carbon chain length of 6 to 12, one of these alone or two or more of them. Can be used in combination.
- the tri fatty acid glyceryl include glyceryl tricaprylate, glyceryl tricaprate, and glyceryl tri (capryl / capric acid).
- tri-fatty acid glyceryl, particularly tri (capryl / capric acid) glyceryl is particularly preferable because it is resistant to discoloration due to oxidation and is stable.
- the amount of oily component in the emulsion is preferably 10 to 60% (mass%, the same applies hereinafter) of the whole emulsion including the dispersion medium, and particularly preferably 20 to 50%.
- the oil component amount is adjusted according to the average particle size of the emulsion particles, and the stability of the emulsion is improved by decreasing the oil component amount as the average particle size decreases. When it is 10% or more, the emulsion can be sufficiently formed. When it is 60% or less, the oily component is not separated, which is suitable for preventing the appearance stability from being impaired.
- one or more nonionic surfactants such as glycerin fatty acid ester, polyoxyethylene hydrogenated castor oil, and polyoxyethylene alkyl ether can be used, and those having an HLB value of 10 to 16 are preferable.
- the glycerin fatty acid ester include decaglycerin monofatty acid ester having 12 to 16 fatty acid carbon atoms such as decaglyceryl monomyristate and decaglyceryl monolaurate.
- the average number of moles of ethylene oxide added to the polyoxyethylene hydrogenated castor oil is preferably 10 to 100 moles, more preferably 20 to 60 moles.
- the average addition mole number of ethylene oxide of polyoxyethylene alkyl ether is preferably 4 to 20 moles, particularly preferably 6 to 15 moles.
- decaglycerin monofatty acid ester and polyoxyethylene hydrogenated castor oil are preferred.
- decaglyceryl monomyristate and polyoxyethylene hydrogenated castor oil are preferred from the viewpoint of appearance stability (freezing / restoring property) during freezing and restoration. preferable.
- the amount of emulsifier added is usually preferably 5 to 30%, more preferably 5 to 20% of the whole emulsion including the dispersion medium.
- the addition amount of the emulsifier is adjusted according to the average particle size of the emulsion particles to be formed, and the stability of the emulsion is improved by increasing the content of the emulsifier as the average particle size becomes smaller. When it is 5% or more, the oily component is not separated, and when it is 30% or less, it is suitable for suppressing gelation.
- the dispersion medium in addition to water, one or more kinds of polyhydric alcohols such as glycerin, propylene glycol, 1,3-butylene glycol, dipropylene glycol and polyethylene glycol having an average molecular weight of 190 to 630 can be used. .
- the above emulsion preferably has an average particle size of emulsion particles of 30 to 300 nm, particularly 40 to 250 nm.
- the average particle size is within the above range, it is more preferable to improve the appearance stability (freezing / restoring property) while suppressing the irritation in the oral cavity and giving a refreshing feeling. If the average particle size is too small, the irritation at the time of use may be strong, and if it is too large, the refreshing feeling after use may not be obtained.
- grains is as showing below.
- a dynamic light scattering photometer DLS-8000 manufactured by Otsuka Electronics Co., Ltd. the emulsion was diluted 1000 times with purified water, placed in a cell, and the average particle size at 25 ° C. was measured.
- emulsion (A) in particular, glycerin or dipropylene glycol and water are used as a dispersion medium, triglyceride glyceryl as an oil component, and average added mole number of decaglycerin monofatty acid ester or ethylene oxide having 12 to 16 fatty acid carbon atoms.
- An O / W type emulsion having an average particle size of emulsion particles of 30 to 250 nm, which is emulsified with polyoxyethylene hydrogenated castor oil having a particle size of 20 to 60 mol, can be suitably added and blended.
- a known method can be adopted as a method for preparing the emulsion. For example, after stirring a predetermined amount of a nonionic surfactant, a polyhydric alcohol as a dispersion medium, and half of water with a homomixer, an oily component is added to form an emulsion, and finally the remaining water is added. W-type emulsions can be prepared. Thereafter, the average particle size of the prepared emulsion can be adjusted using a high-pressure homogenizer. In emulsification with a high-pressure homogenizer, the average particle diameter is adjusted by the difference in shearing force. When the emulsified particles are atomized, the stability over time is further improved.
- a microfluidizer manufactured by Microfluidics International CO
- a gorin homogenizer manufactured by Runny Gorin
- an optimizer manufactured by Sugino Machine
- the pressure during emulsification is usually 30 MPa or more, preferably 30 to 100 MPa.
- the introduction of the oil phase into the aqueous phase and the emulsification operation are preferably performed under a temperature condition of about 25 to 50 ° C.
- the emulsion prepared by the above method can be added and blended as the emulsion (A), but a commercially available product can also be used.
- a commercially available product can also be used.
- NET-TE-50 manufactured by Nikko Chemicals Co., Ltd. can be used.
- the content of the oil component contained in the emulsion particles of the emulsion (A) is preferably 0.02 to 1.0%, more preferably 0.05 to 0.5% of the total composition. %.
- the emulsion (A) is preferably added and blended so that the content of the oil component in the composition is within the above range.
- the content of the oil component contained in the emulsion particles is 0.02% or more, it is possible to prevent the irritation feeling during use from becoming strong.
- it is 1.0% or less appearance stability (freezing / restoring property) at the time of freezing and thawing is improved, and a lack of refreshing feeling after use can be prevented.
- the addition amount of the emulsion (A) (the addition amount of the emulsion including the dispersion medium) is preferably 0.1 to 4%, more preferably 0.2 to 1.0% of the whole composition.
- N-acyl taurine salt as component (B) examples include cocoyl methyl taurine salt, lauroyl methyl taurine salt, myristoyl methyl taurine salt, and the like. These sodium salts are preferably used. Among these, lauroylmethyl taurine salt is preferable from the viewpoint of freezing and restoring property.
- Specific examples of N-acyl taurine salts include commercially available products such as NIKKOL CMT-30, NIKKOL CMT-30T, NIKKOL LMT, NIKKOL LMT-30, NIKKOL LMT-P, and NIKKOL MMT manufactured by Nikko Chemicals.
- the content of the N-acyl taurine salt (B) is 0.2 to 0.8%, preferably 0.3 to 0.5% of the whole composition.
- the effect of this invention can be provided in content being in the said range. If it is less than 0.2%, the turbidity of the composition changes after freezing and the appearance stability (freezing and restoring properties) is impaired. Moreover, a refreshing feeling cannot be imparted to the oral cavity. If it exceeds 0.8%, the stability of the emulsion decreases after freezing and the color tone of the composition fades (transparents), and the appearance stability (freezing and restoring properties) is impaired. Moreover, a feeling of irritation is given to the oral cavity and the feeling of use is impaired.
- the content of the component (B) is preferably adjusted according to the amount of the oil component contained in the emulsion particles of the emulsion (A) within the above range, and is optimal according to the average particle size of the emulsion particles. It is more preferable to adjust the range.
- the content of the oily component contained in the emulsion particles of the emulsion (A) relative to the whole composition (hereinafter abbreviated as the amount of the oily component in the emulsion (A)), the N-acyl taurine salt
- the ratio of the content of (B) to the total composition is preferably 0.15 to 3, more preferably 0 as the mass ratio. .2 to 2.5, more preferably 0.3 to 0.9.
- the appearance stability (freezing / restoring property) particularly during freezing and thawing is further improved, and the effects of the present invention are further improved. If the ratio is too small, sufficient freeze-recoverability may not be obtained, and satisfactory appearance stability may not be imparted. On the other hand, if it is too large, a feeling of irritation is strongly developed and the feeling of use may be lowered.
- the average particle size of the emulsion (A) particles, the content of the N-acyl taurine salt of the component (B), the amount of the oil component in the emulsion (A) / the amount of the component (B) When the ratio is any one of the following combinations, the effect of the present invention is further improved.
- isopropylmethylphenol C
- isopropylmethylphenol C
- isopropylmethylphenol C
- isopropylmethylphenol is added and blended, high biofilm bactericidal power can be imparted with excellent appearance stability (freezing / restoring property).
- Isopropylmethylphenol is a bactericidal component that can be blended in oral products, is blended in liquid preparations such as commercial mouthwashes, and is known to have bactericidal power on biofilms.
- isopropylmethylphenol is poorly water-soluble, it must be solubilized with a surfactant in order to be stably blended in an aqueous solution, and it is known that the level of bactericidal power varies depending on the solubilized state.
- the liquid oral cavity composition of the present invention is prepared as a mouthwash, a liquid dentifrice, and the like, and in addition to the above components, known components according to the dosage form can be blended within a range that does not interfere with the effects of the present invention.
- known components according to the dosage form can be blended within a range that does not interfere with the effects of the present invention.
- wetting agents, thickeners, surfactants, solvents, and if necessary, pH adjusters, sweeteners, colorants, fragrances, active ingredients and the like can be contained.
- wetting agent examples include sugar alcohols such as sorbitol, xylit, malt, and lactit, and polyhydric alcohols such as glycerin and propylene glycol.
- sugar alcohols such as sorbitol, xylit, malt, and lactit
- polyhydric alcohols such as glycerin and propylene glycol.
- the blending amount of these wetting agents is usually 5 to 15%, and the total amount including the dispersion medium of the emulsion (A) is preferably within the above range.
- thickener examples include xanthan gum, sodium alginate, polyvinyl alcohol, hydroxyethyl cellulose and the like (the amount is usually 0 to 1%, particularly 0 to 0.5%).
- a surfactant other than the N-acyl taurine salt generally used in liquid oral compositions is added and blended as a surfactant.
- a surfactant other than the N-acyl taurine salt generally used in liquid oral compositions.
- a surfactant is added and blended as a surfactant.
- a surfactant other than the N-acyl taurine salt generally used in liquid oral compositions is added and blended as a surfactant.
- a surfactant other than the N-acyl taurine salt generally used in liquid oral compositions is added and blended as a surfactant.
- betaine acetate type amphoteric surfactants such as alkyldimethylaminoacetic acid betaines and fatty acid amidopropyldimethylaminoacetic acid betaines as amphoteric surfactants
- N -Imazoline type amphoteric surfactants such as fatty acid acyl-N-carboxymethyl-N-hydroxyethylethylenediamine salts
- the addition amount of these surfactants is preferably 0.1 to 2%, particularly preferably 0.1 to 1.0%.
- the total content of the surfactant including the emulsifier of the emulsion (A) is preferably in the above range, particularly from the viewpoint of the stability of the emulsion. If the addition amount of the surfactant is too small, the freeze-recovery property may be deteriorated, and if it is too much, the emulsion may be dissolved.
- Anionic surfactants other than N-acyl taurine salts particularly alkyl sulfates such as sodium lauryl sulfate and acyl sarcosine salts such as sodium lauroyl sarcosine may not be added, but the effects of the present invention are not hindered. You may add in the range. When added, the addition amount is preferably 0.2% or less, particularly preferably 0.1% or less of the entire composition.
- purified water is generally used, and the blending amount is usually 60% or more.
- pH adjusters include phthalic acid, phosphoric acid, citric acid, succinic acid, acetic acid, fumaric acid, malic acid, carbonic acid, and potassium salts, sodium salts, ammonium salts, ribonucleic acid or salts thereof, sodium hydroxide, etc. Is mentioned.
- the composition of the present invention preferably has a pH of 5.5 to 8.5 at 25 ° C.
- a pH adjuster in the vicinity thereof a combination of citric acid and sodium citrate, phosphoric acid and its sodium salt (especially phosphorous) A combination of sodium dihydrogen acid and sodium monohydrogen phosphate is preferred.
- sweetening agent examples include saccharin sodium, stevocytes, sucralose, reduced palatinose, erythritol and the like.
- coloring agent water-soluble pigments having high safety such as Blue No. 1, Green No. 3, Yellow No. 4, Red No. 105 and the like can be added.
- Perfumes include peppermint oil, spearmint oil, anise oil, eucalyptus oil, winter green oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, Lime oil, lavender oil, rosemary oil, laurel oil, camomil oil, caraway oil, marjoram oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie Natural fragrances such as oil, coconut oil, Iris concrete, absolute peppermint, absolute rose, orange flower, and processing of these natural fragrances (front reservoir cut, rear reservoir cut, fractional distillation, liquid-liquid extraction, essence, powder Perfumes, etc.) and menthol, Rubon, Anethole, Cineol, Methyl salicylate, Synamic aldehyde, Eugenol, 3-l-Mentoxy
- fragrances are preferably 0.00001 to 3% in the composition as long as the effects of the present invention are not hindered.
- a clove oil and / or thyme oil is contained as a fragrance, preferably in the range of 0.00001 to 0.01%, more preferably 0.0001 to 0.003%, The irritation feeling is further suppressed, and the usability of the preparation is further improved.
- flavor (D) containing a clove oil and / or thyme oil so that content of the clove oil and / or thyme oil in a composition may become the said range.
- the pungent taste derived from the N-acyl taurine salt (B) is suppressed, the irritation caused by the pungent taste is also suppressed, and the feeling of use is further improved.
- fungicides such as triclosan, cetylpyridinium chloride, benzethonium chloride, anti-inflammatory agents such as tranexamic acid, epsilon-aminocaproic acid, dextranase, amylase, protease, mutanase, lysozyme , Enzymes such as lytic enzyme, lytechenzyme, fluorides such as sodium fluoride, sodium monofluorophosphate, stannous fluoride, vitamin C such as aluminum chlorohydroxy allantoin, allantoin, azulene, lysozyme chloride, ascorbic acid, Tocopherol acetate, dihydrocholesterol, glycyrrhetin salts, glycyrrhetinic acid, hydrocholesterol, chlorophyll, copper chlorophyllin sodium, thyme, hornon, butterfly Plant extract
- the liquid oral composition of the present invention is preferably substantially free from ethanol from the viewpoint of stabilizing the emulsion.
- substantially free of ethanol means that the amount of ethanol in the composition is preferably 100 ppm or less, more preferably 50 ppm or less, and particularly preferably 10 ppm or less with respect to the whole composition.
- the liquid oral composition may contain a small amount of raw material-derived ethanol in the fragrance blended in the composition even if it is not blended with ethanol, in consideration of these reasons, It is desirable not to contain ethanol in addition to ethanol contained in trace amounts in perfumes.
- Liquid oral compositions (mouthwashes) shown in Tables 1 to 4 were prepared by conventional methods. Appearance stability when freeze-thawed (freezing / restoring) by the following methods, refreshing feeling after use in the oral cavity, when used The lack of irritation was evaluated. Moreover, about the composition for liquid oral cavity which mix
- An O / W type emulsion having the following composition was prepared by the following method. Stirring with a homomixer was carried out at a known high-pressure homogenizer (pressure condition 30 to 100 MPa), charging the oil phase into the aqueous phase, and emulsifying operation at 25 to 50 ° C. The average particle size of the emulsion particles was obtained by diluting the emulsion 1000 times with purified water using a dynamic light scattering photometer DLS-8000 manufactured by Otsuka Electronics Co., Ltd. Was measured.
- Embodision composition > [Emulsion A1 (average particle size 50 nm)] Decaglyceryl monolaurate 20% Tri (capryl / capric acid) glyceryl 20 Glycerin 15 Water 45 Total 100% After pre-stirring glycerin, half amount of water, and decaglyceryl monolaurate, tri (capryl / capric acid) glyceryl was added, stirred with a homomixer, and finally the remaining water was added.
- Embodision A4 (average particle size 100 nm)] Polyoxyethylene (60) hydrogenated castor oil 20% Tri (capryl / capric acid) glyceryl 30 Propylene glycol 10 Water 40 Total 100% After pre-stirring propylene glycol, half amount of water, polyoxyethylene (60) hydrogenated castor oil, tri (capryl / capric acid) glyceryl was added, and the mixture was stirred with a homomixer, and finally the remaining water was added.
- Embodision A5 (average particle size 50 nm)] Polyoxyethylene (20) hydrogenated castor oil 20% Tri (capryl / capric acid) glyceryl 20 Dipropylene glycol 10 Water 50 Total 100% Dipropylene glycol, half amount of water, polyoxyethylene (20) hydrogenated castor oil was pre-stirred, tri (capryl / capric acid) glyceryl was added, stirred with a homomixer, and finally the remaining water was added. .
- the external appearance of the composition for liquid oral cavity of the present invention becomes light cloudy when the particle size of the emulsion is small, and becomes cloudy as the particle size increases.
- the obtained freeze-thawed product was visually observed in accordance with the following criteria in terms of appearance stability (white turbidity of the liquid due to the dispersed emulsion) in comparison with a control product that was allowed to stand at ⁇ 5 ° C. for 24 hours and then at 25 ° C. for 24 hours. Judged. The samples with ⁇ and ⁇ were judged to have good appearance stability (freezing / restoring property). Evaluation criteria for appearance stability (freezing and restoring properties): ⁇ : No change in the turbidity of the liquid ⁇ : A slight change in the turbidity of the liquid is observed ⁇ : A change in the turbidity of the liquid is observed ⁇ : The turbidity of the liquid is greatly changed
- the oral bacteria used for the production of the model biofilm were all purchased from American Type Culture Collection (ATCC). Streptococcus gordonii ATCC 51656 strain and Actinomyces naeslandi ATCC 51655 strain were used as oral resident bacteria, and Porphysis as pathogenic bacteria. Romonas gingivalis strain ATCC33277 was used. These three bacterial species were inoculated into the above culture solution so as to be 2 ⁇ 10 7 cfu / mL (cloning forming units), respectively, and 37 ° C. and anaerobic conditions (80 vol% nitrogen, 10 vol% dioxide dioxide) together with the saliva-treated HA carrier. Carbon (10 vol% hydrogen) was continuously cultured for 2 weeks (the replacement rate of the culture solution was 10 vol%) to form a model biofilm with a mixture of three bacterial species on the HA surface.
- ATCC American Type Culture Collection
- model biofilm was immersed in 2 mL of an evaluation drug (liquid oral composition) for 3 minutes and washed 6 times with 1 mL of sterile physiological saline. Then, model biofilm is dispersed by sonication (200 ⁇ A, 10 seconds) with 4 mL of sterilized physiological saline, smeared on Bacteroides agar plate (blood agar plate with kanamycin added), and anaerobic until colonies can be confirmed with the naked eye. Culture (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) was performed.
- Comparative Examples 1 to 3 lacking the component (B) are inferior in appearance stability (freezing / restoring property) even when they contain anionic surfactant sodium lauryl sulfate and sodium lauroyl sarcosine.
- Comparative Example 4 with a small amount of component was also inferior in appearance stability (freezing / restoring property).
- Comparative Example 5 in which there are too many components (B), the color of the liquid that became cloudy after freezing and restoration was faded (transparent), appearance stability (freezing and restoring properties) was inferior, and a sense of irritation derived from component (B) was expressed. .
- Example 19 to 24 The liquid oral compositions (mouthwashes) of Examples 19 to 24 shown in Table 5 were prepared in the same manner as described above, and the appearance stability (freezing / restoring property) during freezing and thawing was used in the same manner as above. The refreshing feeling later, lack of irritation at the time of use, and biofilm sterilizing power were evaluated, and the lack of pungent taste at the time of use was evaluated by the following method. Moreover, the nonpungency of Example 10 shown in Table 3 was evaluated similarly, and the said result was written together in Table 5 with this result.
- the fragrances a to f used in Examples 19 to 24 all contain clove oil and thyme oil. Table 5 shows the contents of clove oil and thyme oil in the compositions of each example. It is shown.
- a prescription example is shown below.
- the raw materials used are the same as described above.
- Mouthwash A) Emulsion A1 (average particle size 50 nm) 0.5% Content of oily component in emulsion (A) 0.10% (B) Lauroylmethyl taurine sodium 0.3% Sodium fluoride 0.05% Copper gluconate 0.05% Glycerin 3% Propylene glycol 4% Polyoxyethylene (60) hydrogenated castor oil 0.20% Citric acid 0.70% Sodium citrate 0.3% Perfume containing clove oil and thyme oil 0.2% Content of clove oil in the composition 0.00001% Content of thyme oil in the composition 0.00001% Water remaining Total 100%
- Mouthwash A) Emulsion A1 (average particle size 50 nm) 0.5% Content of oily component in emulsion (A) 0.10% (B) Lauroylmethyl taurine sodium 0.3% (C) Isopropyl methylphenol 0.05% Sodium fluoride 0.02% Glycerin 3% Propylene glycol 4% Polyoxyethylene (60) hydrogenated castor oil 0.20% Citric acid 0.70% Sodium citrate 0.3% Perfume containing clove oil and thyme oil 0.2% Content of clove oil in the composition 0.00001% Content of thyme oil in the composition 0.00001% Water remaining Total 100%
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
なお、上記特許文献は、低温過酷条件保存で凍結時の復元性について言及がない。
また更に、クローブ油及び/又はタイム油を含む香料(D)を配合すると、N-アシルタウリン塩(B)に由来する辛味が抑えられ、辛味による刺激感も抑制され、より優れた使用感を付与できる。
〔1〕
油性成分が25℃で液体の油脂からなるエマルション(A)と、N-アシルタウリン塩(B)とを含有し、N-アシルタウリン塩(B)の含有量が0.2~0.8質量%であることを特徴とする液体口腔用組成物。
〔2〕
油性成分が、オリーブ油、ツバキ油、ヒマシ油及び脂肪酸の炭素数が6~12であるトリ脂肪酸グリセリルから選ばれる1種又は2種以上の油脂である〔1〕記載の液体口腔用組成物。
〔3〕
エマルション(A)のエマルション粒子中に含まれる油性成分の含有量が、組成物全体の0.02~1.0質量%である〔1〕又は〔2〕記載の液体口腔用組成物。
〔4〕
(エマルション(A)のエマルション粒子中に含まれる油性成分の含有量)/(N-アシルタウリン塩(B)の含有量)が、質量比として0.15~3である〔1〕、〔2〕又は〔3〕記載の液体口腔用組成物。
〔5〕
エマルション(A)が、多価アルコール及び水を分散媒とし、油性成分をノニオン性界面活性剤によって乳化した、O/W型のエマルションである〔1〕~〔4〕のいずれかに記載の液体口腔用組成物。
〔6〕
更に、イソプロピルメチルフェノール(C)を0.01~0.2質量%含有する〔1〕~〔5〕のいずれかに記載の液体口腔用組成物。
〔7〕
更に、クローブ油及び/又はタイム油を含む香料(D)を含有し、前記クローブ油及び/又はタイム油の含有量が組成物全体の0.00001~0.01質量%である〔1〕~〔6〕のいずれかに記載の液体口腔用組成物。
〔8〕
界面活性剤の総含有量が0.1~2質量%である〔1〕~〔7〕のいずれかに記載の液体口腔用組成物。
〔9〕
組成物中のエタノールの含有量が100ppm以下である〔1〕~〔8〕のいずれかに記載の液体口腔用組成物。
〔10〕
油性成分が25℃で液体の油脂からなるエマルション(A)を配合した液体口腔用組成物に、N-アシルタウリン塩(B)を0.2~0.8質量%配合する、前記液体口腔用組成物の凍結復元性向上方法。
〔11〕
エマルション(A)のエマルション粒子中に含まれる油性成分の含有量が、組成物全体の0.02~1.0質量%である〔10〕記載の液体口腔用組成物の凍結復元性向上方法。
〔12〕
(エマルション(A)のエマルション粒子中に含まれる油性成分の含有量)/(N-アシルタウリン塩(B)の含有量)を、質量比として0.15~3とする〔10〕又は〔11〕記載の液体口腔用組成物の凍結復元性向上方法。
〔13〕
エマルション(A)が、多価アルコール及び水を分散媒とし、油性成分をノニオン性界面活性剤によって乳化した、O/W型のエマルションである〔10〕、〔11〕又は〔12〕記載の液体口腔用組成物の凍結復元性向上方法。
〔14〕
界面活性剤の総含有量を0.1~2質量%とする〔10〕~〔13〕のいずれかに記載の液体口腔用組成物の凍結復元性向上方法。
〔15〕
組成物中のエタノールの含有量を100ppm以下とする〔10〕~〔14〕のいずれかに記載の液体口腔用組成物の凍結復元性向上方法。
〔16〕
更に、イソプロピルメチルフェノール(C)を0.01~0.2質量%配合する、〔10〕~〔15〕のいずれかに記載の液体口腔用組成物の凍結復元性向上方法。
〔17〕
更に、クローブ油及び/又はタイム油を含む香料(D)を、前記クローブ油及び/又はタイム油の含有量が組成物全体の0.00001~0.01質量%となるように配合する、〔10〕~〔15〕のいずれかに記載の液体口腔用組成物の凍結復元性向上方法。
これらの中で、デカグリセリンモノ脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油が好ましく、特に凍結復元での外観安定性(凍結復元性)の点から、モノミリスチン酸デカグリセリル、ポリオキシエチレン硬化ヒマシ油が好ましい。
大塚電子(株)製、ダイナミック光散乱光度計DLS-8000を用いて、エマルションを精製水で1000倍希釈し、セルに入れて25℃での平均粒径を測定した。
例えば、所定量のノニオン界面活性剤、分散媒の多価アルコール、及び半量の水をホモミキサーで撹拌後、油性成分を加え、エマルションを形成させ、最後に残りの水を加えることで、O/W型エマルションを調製することができる。その後、調製したエマルションは、高圧ホモジナイザーを用いて平均粒径を調節することができる。
高圧ホモジナイザーによる乳化では、剪断力の違いにより平均粒径が調整される。乳化粒子が微粒化すると、経時における安定性がさらに向上する。高圧ホモジナイザーとしては、マイクロフルイダイザー(マイクロフルイデックス インターナショナル CO社製)、ゴーリンホモジナイザー(ラニーゴーリン社製)、アルティマイザー(スギノマシン社製)などを使用し得るが、これらの機種に限定されず、同様な機構であればどのような機種でもよい。乳化(高圧乳化)時の圧力は通常、30MPa以上であり、30~100MPaが好ましい。油相の水相への投入、乳化操作は、25~50℃程度の温度条件下で行うことが好ましい。
なお、エマルション(A)の添加量(分散媒も含めたエマルションの添加量)は、組成物全体の0.1~4%が好ましく、より好ましくは0.2~1.0%である。
N-アシルタウリン塩として具体的には、日光ケミカルズ社製のNIKKOL CMT-30、NIKKOL CMT-30T、NIKKOL LMT、NIKKOL LMT-30、NIKKOL LMT-P、NIKKOL MMTなどの市販品を使用できる。
なお、(B)成分の含有量は、上記範囲内において、エマルション(A)のエマルション粒子中に含まれる油性成分量に応じて調整することが好ましく、エマルション粒子の平均粒径にも応じた最適範囲に調整することがより好ましい。
(i)
エマルション(A)の粒子の平均粒径;30~250nm
N-アシルタウリン塩(B)の含有量;0.2~0.8%
(エマルション(A)中の油性成分量)/(B)成分量;質量比で0.20~1.0
(ii)
エマルション(A)の粒子の平均粒径;40~200nm
N-アシルタウリン塩(B)の含有量;0.2~0.6%
(エマルション(A)中の油性成分量)/(B)成分量;質量比で0.25~0.8
(iii)
エマルション(A)の粒子の平均粒径;40~100nm
N-アシルタウリン塩(B)の含有量;0.2~0.4%
(エマルション(A)中の油性成分量)/(B)成分量;質量比で0.3~0.7
イソプロピルメチルフェノールは、口腔製品に配合可能な殺菌成分であり、市販洗口剤等の液体製剤に配合されおり、バイオフィルムへの殺菌力を有することが知られている。しかし、イソプロピルメチルフェノールは難水溶性であるため、水溶液に安定配合するには界面活性剤で可溶化する必要があり、可溶化状態によって殺菌力のレベルが変化することが知られている。本発明の構成にイソプロピルメチルフェノール(C)を添加した場合、予想外に優れたバイオフィルム殺菌効果が得られることがわかった。本発明組成物にイソプロピルメチルフェノールを添加する場合は、組成物全体の0.01~0.2%、特に0.02~0.1%が好ましい。
本発明では、エマルション(A)の乳化剤を含めた界面活性剤の総含有量が上記範囲内であることが、とりわけエマルションの安定性の点から望ましい。界面活性剤の添加量が少なすぎると、凍結復元性が悪くなる場合があり、多すぎると、エマルションが溶解されてしまう場合がある。
pH調整剤としては、フタル酸、リン酸、クエン酸、コハク酸、酢酸、フマル酸、リンゴ酸、炭酸や、これらのカリウム塩、ナトリウム塩、アンモニウム塩、リボ核酸又はその塩、水酸化ナトリウムなどが挙げられる。なお、本発明組成物は、25℃でpH5.5~8.5であることが好ましく、この付近のpH調整剤としてクエン酸とクエン酸ナトリウムとの組み合わせ、リン酸とそのナトリウム塩(特にリン酸二水素ナトリウムとリン酸一水素ナトリウム)との組み合わせが好ましい。
着色料として、青色1号、緑色3号、黄色4号、赤色105号等の安全性の高い水溶性色素を添加できる。
なお、本発明では、香料として、特にクローブ油及び/又はタイム油を、組成物全体の好ましくは0.00001~0.01%、より好ましくは0.0001~0.003%含有すると、使用時の刺激感がさらに抑えられ、製剤の使用感がより向上する。
この場合、クローブ油及び/又はタイム油を含む香料(D)を、組成物中のクローブ油及び/又はタイム油の含有量が上記範囲になるように配合することが好ましい。クローブ油及び/又はタイム油の含有量が上記範囲内であると、N-アシルタウリン塩(B)に由来する辛味が抑えられ、辛味による刺激感も抑制されて使用感がより向上する。
表1~4に示す液体口腔用組成物(洗口剤)を常法により調製し、下記方法で凍結融解時の外観安定性(凍結復元性)、口腔内で使用後のスッキリ感、使用時の刺激感のなさを評価した。また、表3、4に示すイソプロピルメチルフェノールを配合した液体口腔用組成物については、更に下記方法でバイオフィルム殺菌力を評価した。結果を表1~4に併記した。
なお、使用したエマルションの調製方法、組成は下記の通りである。調製したエマルションA1~A5を、表中に示す量で配合した。
下記組成のO/W型エマルションを下記方法で調製した。なお、ホモミキサーによる攪拌は公知の高圧ホモジナイザー(圧力条件30~100MPa)、油相の水相への投入、乳化操作は25~50℃で行った。
また、エマルション粒子の平均粒子径は、大塚電子(株)製、ダイナミック光散乱光度計DLS-8000を用いて、エマルションを精製水で1000倍希釈し、セルに入れて25℃での平均粒径を測定した。
[エマルションA1(平均粒径50nm)]
モノラウリン酸デカグリセリル 20%
トリ(カプリル・カプリン酸)グリセリル 20
グリセリン 15
水 45
合計 100%
グリセリン、半量の水、モノラウリン酸デカグリセリルを予備撹拌後、トリ(カプリル・カプリン酸)グリセリルを加えて、ホモミキサーで撹拌し、最後に残りの水を加えて調製した。
モノミリスチン酸デカグリセリル 10%
トリ(カプリル・カプリン酸)グリセリル 50
グリセリン 15
水 25
合計 100%
グリセリン、半量の水、モノミリスチン酸デカグリセリルを予備撹拌後、トリ(カプリル・カプリン酸)グリセリルを加えて、ホモミキサーで撹拌し、最後に残りの水を加えて調製した。
モノラウリン酸デカグリセリル 10%
トリ(カプリル・カプリン酸)グリセリル 30
グリセリン 15
水 45
合計 100%
グリセリン、半量の水、モノラウリン酸デカグリセリルを予備撹拌後、トリ(カプリル・カプリン酸)グリセリルを加えて、ホモミキサーで撹拌し、最後に残りの水を加えて調製した。
ポリオキシエチレン(60)硬化ヒマシ油 20%
トリ(カプリル・カプリン酸)グリセリル 30
プロピレングリコール 10
水 40
合計 100%
プロピレングリコール、半量の水、ポリオキシエチレン(60)硬化ヒマシ油を予備撹拌後、トリ(カプリル・カプリン酸)グリセリルを加えて、ホモミキサーで撹拌し、最後に残りの水を加えて調製した。
ポリオキシエチレン(20)硬化ヒマシ油 20%
トリ(カプリル・カプリン酸)グリセリル 20
ジプロピレングリコール 10
水 50
合計 100%
ジプロピレングリコール、半量の水、ポリオキシエチレン(20)硬化ヒマシ油を予備撹拌後、トリ(カプリル・カプリン酸)グリセリルを加えて、ホモミキサーで撹拌し、最後に残りの水を加えて調製した。
ラウロイルメチルタウリンナトリウム;日光ケミカルズ(株)製
イソプロピルメチルフェノール;大阪化成(株)製
ポリオキシエチレン(60)硬化ヒマシ油;
エチレンオキサイドの平均付加モル数60、日光ケミカルズ(株)製
なお、使用した香料はクローブ油及びタイム油を含有し、表1~4に示す実施例及び比較例は、それぞれ組成物中にクローブ油を0.00001%、タイム油を0.00001%含有する。
エマルション配合の液体口腔用組成物の外観は、エマルションの散乱現象により液が白濁している。エマルションの安定性が悪い場合には凝集、合一や可溶化などが起こり、凝集、合一で粒径が大きくなることで白濁度が増したり、逆に配合している界面活性剤等の影響で可溶化が進むと白濁度が減少するなどの変化が観察される。このことから、エマルションの安定性を液体口腔用組成物の白濁度の変化を指標に目視で評価した。
なお、本発明の液体口腔用組成物の外観は、エマルションの粒径が小さい場合にはうすい白濁となり、粒径が大きくなるに従い白濁となる。
サンプル(液体口腔用組成物)を満注量500mLの無色透明なPET容器(吉野工業所製)に450mL充填し、-20℃の状態で凍結させ24時間放置し、その後、25℃の状態で24時間放置し試料を融解させた。この作業を1サイクルとし、5回繰り返した。得られた凍結融解品について、外観安定性(分散したエマルションによる液の白濁度)を、-5℃で24時間、その後に25℃で24時間放置した対照品と比べて下記基準に則り、目視判定した。◎、○のものを外観安定性(凍結復元性)がよいと判断した。
外観安定性(凍結復元性)の評価基準:
◎:液の白濁度に変化は認められない
○:液の白濁度に僅かに変化が認められる
△:液の白濁度に変化が認められる
×:液の白濁度が大きく変化している
評価者10名が各液体口腔用組成物10mLを口に含み、30秒間すすいだ後、洗口後のスッキリ感について評価した。下記の4段階の評点基準で評価し、10名の平均点から下記評価基準に従って判定した。
評点基準:
4点:高いスッキリ感を得た
3点:やや高いスッキリ感を得た
2点:ごくわずかにスッキリ感を得た
1点:ほとんどスッキリ感が得られなかった
洗口後のスッキリ感の評価基準:
◎:平均点3.5点以上4.0点以下
○:平均点3.0点以上3.5点未満
△:平均点2.0点以上3.0点未満
×:平均点2.0点未満
評価者10名が各液体口腔用組成物10mLを口に含み、30秒間すすいで洗口した時の刺激感のなさについて評価した。下記の4段階の評点基準で評価し、10名の平均点から下記の評価基準に従って判定した。
評点基準:
4点:刺激がなかった
3点:刺激がほとんどなかった
2点:刺激がややあった
1点:刺激がかなりあった
洗口時の刺激感の評価基準:
◎:平均点3.5点以上4.0点以下
○:平均点3.0点以上3.5点未満
△:平均点2.0点以上3.0点未満
×:平均点2.0点未満
直径7mm×厚さ3.5mmのハイドロキシアパタイト(HA)板(旭光学社製)を、0.45μmのフィルターでろ過したヒト無刺激唾液で4時間処理したものを、モデルバイオフィルム作製担体に用いた。
培養液は、トリプチケースソイブロス(Difco社製)30gを1Lの精製水に溶解した液にヘミン(Sigma社製)5mg/L、ビタミンK(和光純薬工業社製)1mg/Lを添加したものを用いた。
モデルバイオフィルムの作製に用いた口腔細菌は、いずれもアメリカン タイプ カルチャー コレクション(ATCC)より購入したもので、口腔常在細菌としてストレプトコッカス ゴルドニアイ ATCC51656株及びアクチノマイセス ナエスランディ ATCC51655株、病原性細菌としてポルフィロモナス ジンジバリスATCC33277株を用いた。
これら3菌種をそれぞれ2×107cfu/mL(clony forming units)になるように上述の培養液に接種し、唾液処理したHA担体と共に37℃、嫌気条件下(80vol%窒素、10vol%二酸化炭素、10vol%水素)で2週間連続培養(培養液の置換率は10vol%とした)を行い、HA表面に3菌種混合のモデルバイオフィルムを形成させた。
評価基準:
◎:106未満
○:106以上107未満
△:107以上108未満
×:108以上
表5に示す実施例19~24の液体口腔用組成物(洗口剤)を上記と同様に調製し、上記と同様にして凍結融解時の外観安定性(凍結復元性)、口腔内で使用後のスッキリ感、使用時の刺激感のなさ、バイオフィルム殺菌力を評価し、下記方法で使用時の辛味のなさを評価した。また、表3に示す実施例10の辛味のなさを同様に評価し、この結果と共に上記結果を表5に併記した。
なお、実施例19~24で使用した香料a~fは、いずれもクローブ油及びタイム油を含有し、各例の組成物中のクローブ油の含有量、タイム油の含有量は、表5に示すとおりである。
評価者10名が各液体口腔用組成物10mLを口に含み、30秒間すすいで洗口した時の辛味のなさについて評価した。下記の4段階の評点基準で評価し、10名の平均点から下記の評価基準に従って判定した。
評点基準:
4点:辛味がなかった
3点:辛味がほとんどなかった
2点:辛味がややあった
1点:辛味がかなりあった
洗口時の辛味のなさの評価基準:
◎:平均点3.5点以上4.0点以下
○:平均点3.0点以上3.5点未満
△:平均点2.0点以上3.0点未満
×:平均点2.0点未満
(A)エマルションA1(平均粒径50nm) 0.5%
エマルション(A)中の油性成分の含有量 0.10%
(B)ラウロイルメチルタウリンナトリウム 0.3%
フッ化ナトリウム 0.05%
グルコン酸銅 0.05%
グリセリン 3%
プロピレングリコール 4%
ポリオキシエチレン(60)硬化ヒマシ油 0.20%
クエン酸 0.70%
クエン酸ナトリウム 0.3%
クローブ油及びタイム油を含む香料 0.2%
組成物中のクローブ油の含有量 0.00001%
組成物中のタイム油の含有量 0.00001%
水 残
合計 100%
(A)エマルションA1(平均粒径50nm) 0.5%
エマルション(A)中の油性成分の含有量 0.10%
(B)ラウロイルメチルタウリンナトリウム 0.3%
(C)イソプロピルメチルフェノール 0.05%
アラントイン 0.05%
グリセリン 3%
プロピレングリコール 4%
ポリオキシエチレン(60)硬化ヒマシ油 0.20%
クエン酸 0.70%
クエン酸ナトリウム 0.3%
クローブ油及びタイム油を含む香料 0.2%
組成物中のクローブ油の含有量 0.00001%
組成物中のタイム油の含有量 0.00001%
水 残
合計 100%
(A)エマルションA1(平均粒径50nm) 0.5%
エマルション(A)中の油性成分の含有量 0.10%
(B)ラウロイルメチルタウリンナトリウム 0.3%
(C)イソプロピルメチルフェノール 0.05%
フッ化ナトリウム 0.02%
グリセリン 3%
プロピレングリコール 4%
ポリオキシエチレン(60)硬化ヒマシ油 0.20%
クエン酸 0.70%
クエン酸ナトリウム 0.3%
クローブ油及びタイム油を含む香料 0.2%
組成物中のクローブ油の含有量 0.00001%
組成物中のタイム油の含有量 0.00001%
水 残
合計 100%
Claims (15)
- 油性成分が25℃で液体の油脂からなるエマルション(A)と、N-アシルタウリン塩(B)とを含有し、N-アシルタウリン塩(B)の含有量が0.2~0.8質量%であることを特徴とする液体口腔用組成物。
- 油性成分が、オリーブ油、ツバキ油、ヒマシ油及び脂肪酸の炭素数が6~12であるトリ脂肪酸グリセリルから選ばれる1種又は2種以上の油脂である請求項1記載の液体口腔用組成物。
- エマルション(A)のエマルション粒子中に含まれる油性成分の含有量が、組成物全体の0.02~1.0質量%である請求項1又は2記載の液体口腔用組成物。
- (エマルション(A)のエマルション粒子中に含まれる油性成分の含有量)/(N-アシルタウリン塩(B)の含有量)が、質量比として0.15~3である請求項1、2又は3記載の液体口腔用組成物。
- エマルション(A)が、多価アルコール及び水を分散媒とし、油性成分をノニオン性界面活性剤によって乳化した、O/W型のエマルションである請求項1乃至4のいずれか1項記載の液体口腔用組成物。
- 更に、イソプロピルメチルフェノール(C)を0.01~0.2質量%含有する請求項1乃至5のいずれか1項記載の液体口腔用組成物。
- 更に、クローブ油及び/又はタイム油を含む香料(D)を含有し、前記クローブ油及び/又はタイム油の含有量が組成物全体の0.00001~0.01質量%である請求項1乃至6のいずれか1項記載の液体口腔用組成物。
- 界面活性剤の総含有量が0.1~2質量%である請求項1乃至7のいずれか1項記載の液体口腔用組成物。
- 組成物中のエタノールの含有量が100ppm以下である請求項1乃至8のいずれか1項記載の液体口腔用組成物。
- 油性成分が25℃で液体の油脂からなるエマルション(A)を配合した液体口腔用組成物に、N-アシルタウリン塩(B)を0.2~0.8質量%配合する、前記液体口腔用組成物の凍結復元性向上方法。
- エマルション(A)のエマルション粒子中に含まれる油性成分の含有量が、組成物全体の0.02~1.0質量%である請求項10記載の液体口腔用組成物の凍結復元性向上方法。
- (エマルション(A)のエマルション粒子中に含まれる油性成分の含有量)/(N-アシルタウリン塩(B)の含有量)を、質量比として0.15~3とする請求項10又は11記載の液体口腔用組成物の凍結復元性向上方法。
- エマルション(A)が、多価アルコール及び水を分散媒とし、油性成分をノニオン性界面活性剤によって乳化した、O/W型のエマルションである請求項10、11又は12記載の液体口腔用組成物の凍結復元性向上方法。
- 界面活性剤の総含有量を0.1~2質量%とする請求項10乃至13のいずれか1項記載の液体口腔用組成物の凍結復元性向上方法。
- 組成物中のエタノールの含有量を100ppm以下とする請求項10乃至14のいずれか1項記載の液体口腔用組成物の凍結復元性向上方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580021118.5A CN106456485B (zh) | 2014-04-21 | 2015-04-20 | 液体口腔用组合物以及改善其冷冻复原性的方法 |
KR1020167029282A KR102345066B1 (ko) | 2014-04-21 | 2015-04-20 | 액체 구강용 조성물 및 그 동결 복원성 향상 방법 |
JP2016514923A JP6512218B2 (ja) | 2014-04-21 | 2015-04-20 | 液体口腔用組成物及びその凍結復元性向上方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-087254 | 2014-04-21 | ||
JP2014087254 | 2014-04-21 | ||
JP2014-112323 | 2014-05-30 | ||
JP2014112323 | 2014-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015163284A1 true WO2015163284A1 (ja) | 2015-10-29 |
Family
ID=54332450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/061990 WO2015163284A1 (ja) | 2014-04-21 | 2015-04-20 | 液体口腔用組成物及びその凍結復元性向上方法 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6512218B2 (ja) |
KR (1) | KR102345066B1 (ja) |
CN (1) | CN106456485B (ja) |
MY (1) | MY180534A (ja) |
WO (1) | WO2015163284A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017114823A (ja) * | 2015-12-25 | 2017-06-29 | 日油株式会社 | 濃縮抗菌剤組成物 |
WO2023120516A1 (ja) * | 2021-12-21 | 2023-06-29 | 小林製薬株式会社 | 液体口腔用組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101956579B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 치약 조성물 |
KR101956578B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011077847A1 (ja) * | 2009-12-22 | 2011-06-30 | ライオン株式会社 | 乳化型液体口腔用組成物及びその製造方法 |
JP2011168506A (ja) * | 2010-02-16 | 2011-09-01 | Lion Corp | 口腔用組成物の製造方法 |
JP2013116884A (ja) * | 2011-10-24 | 2013-06-13 | Shiseido Co Ltd | O/w乳化組成物の製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3938632B2 (ja) | 1998-05-27 | 2007-06-27 | 花王株式会社 | 口腔用組成物 |
JP2005179231A (ja) | 2003-12-18 | 2005-07-07 | Lion Corp | 液体口腔用組成物 |
JP5043588B2 (ja) | 2007-10-12 | 2012-10-10 | 花王株式会社 | 液体口腔用組成物 |
MY157740A (en) | 2010-03-19 | 2016-07-15 | Lion Corp | Liquid oral composition and method for producing same |
JP5584524B2 (ja) * | 2010-06-07 | 2014-09-03 | 花王株式会社 | 水中油型乳化組成物及びその製造方法 |
US9084902B2 (en) | 2010-06-30 | 2015-07-21 | Mcneil-Ppc, Inc. | Non-alchohol bioactive essential oil mouth rinses |
-
2015
- 2015-04-20 WO PCT/JP2015/061990 patent/WO2015163284A1/ja active Application Filing
- 2015-04-20 KR KR1020167029282A patent/KR102345066B1/ko active IP Right Grant
- 2015-04-20 JP JP2016514923A patent/JP6512218B2/ja active Active
- 2015-04-20 CN CN201580021118.5A patent/CN106456485B/zh active Active
- 2015-04-20 MY MYPI2016703646A patent/MY180534A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011077847A1 (ja) * | 2009-12-22 | 2011-06-30 | ライオン株式会社 | 乳化型液体口腔用組成物及びその製造方法 |
JP2011168506A (ja) * | 2010-02-16 | 2011-09-01 | Lion Corp | 口腔用組成物の製造方法 |
JP2013116884A (ja) * | 2011-10-24 | 2013-06-13 | Shiseido Co Ltd | O/w乳化組成物の製造方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017114823A (ja) * | 2015-12-25 | 2017-06-29 | 日油株式会社 | 濃縮抗菌剤組成物 |
WO2023120516A1 (ja) * | 2021-12-21 | 2023-06-29 | 小林製薬株式会社 | 液体口腔用組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR20160145601A (ko) | 2016-12-20 |
KR102345066B1 (ko) | 2021-12-30 |
CN106456485A (zh) | 2017-02-22 |
JP6512218B2 (ja) | 2019-05-15 |
JPWO2015163284A1 (ja) | 2017-04-13 |
MY180534A (en) | 2020-12-01 |
CN106456485B (zh) | 2019-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5690811B2 (ja) | 液体口腔用組成物及びその製造方法 | |
JP5573111B2 (ja) | イソプロピルメチルフェノール含有液体口腔用組成物 | |
JP6318487B2 (ja) | 口腔用組成物 | |
JPWO2007148551A1 (ja) | イソプロピルメチルフェノール含有液体口腔用組成物 | |
KR20190139199A (ko) | 구강 바이오필름 제거제 및 구강용 조성물 | |
JP5853387B2 (ja) | 液体口腔用組成物及び該組成物へ成分を安定化配合する方法 | |
JP6512218B2 (ja) | 液体口腔用組成物及びその凍結復元性向上方法 | |
JP6413815B2 (ja) | 液体口腔用組成物 | |
JP4985907B2 (ja) | 練歯磨組成物 | |
JP5690744B2 (ja) | 乳化型液体口腔用組成物及びその製造方法 | |
JP2015089870A (ja) | 液体口腔用組成物 | |
JP6610001B2 (ja) | 液体口腔用組成物 | |
WO2017209088A1 (ja) | 口腔用組成物 | |
JP2014214107A (ja) | 歯磨組成物 | |
JP2006124315A (ja) | 口腔用組成物 | |
WO2012073602A1 (ja) | 歯磨剤組成物 | |
JP6331641B2 (ja) | 液体口腔用組成物、その製造方法及び前記組成物でのアラントイン又はその誘導体の低温安定化方法 | |
JP6614071B2 (ja) | 液体口腔用組成物 | |
CN116568269A (zh) | 洁齿剂组合物 | |
WO2019049988A1 (ja) | 口腔バイオフィルム除去剤及びこれを含有する口腔用組成物 | |
JP2024030671A (ja) | 口腔用組成物 | |
JP2019048801A (ja) | 液体口腔用組成物 | |
JP2020070263A (ja) | 液体口腔用組成物 | |
JP2019048802A (ja) | 口腔バイオフィルム除去剤及びこれを含有する口腔用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15782643 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016514923 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167029282 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15782643 Country of ref document: EP Kind code of ref document: A1 |